By: IPP Bureau
Last updated : April 04, 2025 11:16 am
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
Roche announced that new data were presented at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria.
Highlights included presentations from the ongoing trontinemab Phase Ib/IIa Brainshuttle AD study demonstrating dose-dependent rapid amyloid depletion from the brain and the potential of the Elecsys pTau181 plasma test to rule out amyloid pathology. Roche also announced the initiation of a Phase III programme for trontinemab, which is expected later this year.
“We are pleased with the progress across our Alzheimer’s portfolio as we move ahead with a Phase III trontinemab programme and continue to expand our diagnostic solutions,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Well over 55 million people worldwide are living with dementia, of which around 70% have Alzheimer's. Moreover, up to three-quarters of people experiencing symptoms of Alzheimer's remain undiagnosed. This growing population needs more accurate, less invasive diagnostic approaches paired with effective disease-modifying treatments to slow neurodegeneration as early as possible.”